MARKET

FLDM

FLDM

Fluidigm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.28
+0.61
+12.96%
Opening 13:22 05/11 EDT
OPEN
4.520
PREV CLOSE
4.670
HIGH
5.45
LOW
4.500
VOLUME
4.39M
TURNOVER
--
52 WEEK HIGH
12.45
52 WEEK LOW
3.330
MARKET CAP
395.43M
P/E (TTM)
-6.9326
1D
5D
1M
3M
1Y
5Y
RXT, DDD, REAL and RBLX among midday movers
Gainers: Sequential Brands (SQBG) +59%.Ferro (FOE) +25%.3D Systems (DDD) +24%.Applied DNA Sciences (APDN) +23%.ShockWave Medical (SWAV) +23%.FutureFuel (FF) +22%.Roblox (RBLX) +16%.Lava Therapeutics (LVTX) +15%.Domtar (UFS) +15%.Fluidigm (FLDM) +15%.Losers...
Seekingalpha · 41m ago
45 Stocks Moving In Tuesday's Mid-Day Session
Gainers Sequential Brands Group, Inc. (NASDAQ: SQBG) surged 52.6% to $14.76 after dropping 11% on Monday.
Benzinga · 1h ago
Fluidigm, ShockWave Medical leads healthcare gainers; Larimar Therapeutics, Nano-X Imaging among major losers
Gainers: Fluidigm (FLDM) +14%, ShockWave Medical (SWAV) +14%, Precision BioSciences (DTIL) +10%, Ekso Bionics (EKSO) +9%, Cerecor (CERC) +5%.Losers: Larimar Therapeutics (LRMR) -20%, Nano-X Imaging (NNOX) -17%, PMV Pharmaceuticals (PMVP) -13%, Novavax (NVA...
Seekingalpha · 2h ago
Deals of the day-Mergers and acquisitions
reuters.com · 7h ago
Activist Investor Caligan Takes 11.2% Stake in Fluidigm
MT Newswires · 12h ago
Fluidigm gains after report that activist takes 11% stake, may push for unit sale
Fluidigm Corp. (FLDM) rose 2.8% after a report that activist investor Caligan Partners has accumulated an 11% stake in the Covid-19 test maker and may ask the company to consider the sale
Seekingalpha · 16h ago
BRIEF-Caligan Partners Lp Reports 11.2% Stake In Fluidigm Corp
reuters.com · 18h ago
Caligan takes stake in COVID-19 test maker Fluidigm, may eye changes
Activist investor Caligan Partners built an 11% stake in Fluidigm Corp, which makes a COVID-19 test, and may urge the company to conduct a strategic review and explore a sale of one of its business units, two sources said on Monday.
Reuters · 19h ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FLDM. Analyze the recent business situations of Fluidigm through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average FLDM stock price target is 9.67 with a high estimate of 12.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 206
Institutional Holdings: 68.29M
% Owned: 91.10%
Shares Outstanding: 74.96M
TypeInstitutionsShares
Increased
54
8.80M
New
37
1.76M
Decreased
33
7.26M
Sold Out
27
4.53M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-0.31%
Healthcare Equipment & Supplies
-0.46%
Key Executives
Chairman/Independent Director
Carlos Paya
President/Chief Executive Officer/Director
Stephen Linthwaite
Chief Financial Officer
Vikram Jog
Senior Vice President/General Counsel/Secretary
Nicholas Khadder
Senior Vice President
Bradley Kreger
Senior Vice President
Brad Kreger
Other
Colin McCracken
Director
Ana Stankovic
Independent Director
Nicolas Barthelemy
Independent Director
Gerhard Burbach
Independent Director
Laura Clague
Independent Director
Bill Colston
No Data
About FLDM
Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company's core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. Its products include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits (IFCs), and assays and reagents. Its preparatory instruments include C1 Single-Cell Auto Prep System, Access Array System, Juno System and IFCs, and Callisto System and IFC. Its analytical instruments include Biomark HD System, EP1 System and Helios/CyTOF 2 System. Its assays and reagents include Delta Gene and SNP Type Assays, and Access Array Target-Specific Primers and Targeted Sequencing Prep Primers.

Webull offers kinds of Fluidigm Corporation stock information, including NASDAQ:FLDM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FLDM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FLDM stock methods without spending real money on the virtual paper trading platform.